Group 1 - The core point of the article is that Fuyuan Pharmaceutical has received the drug registration certificate for Lansoprazole enteric-coated capsules from the National Medical Products Administration, allowing the company to commence production of the drug [2] Group 2 - The approved specifications for the drug are 15mg and 30mg [2] - This approval represents a significant milestone for the company in expanding its product offerings in the pharmaceutical market [2] - The announcement was made on the evening of July 31 [2]

Group 1 - Jiejia Weichuang expects a net profit of 1.7 billion to 1.96 billion yuan for the first half of 2025, representing a year-on-year increase of 38.65% to 59.85% [1] - Micron Biotech's CS231295 clinical trial application has been approved by the FDA for treating advanced solid tumors [1] - Sinopec anticipates a net profit of 20.1 billion to 21.6 billion yuan for the first half of 2025, a decrease of 39.5% to 43.7% year-on-year [2] Group 2 - High Energy Environment has obtained a loan commitment letter from a financial institution for share repurchase [2] - Electric Power Investment Energy received a warning letter from the Inner Mongolia Securities Regulatory Bureau for inadequate disclosure in its semi-annual report [3] - Zhejiang University Net New won a bid for an intelligent engineering project worth 94.2712 million yuan [5] Group 3 - Daodaoquan reported a net profit of 181 million yuan for the first half of 2025, a year-on-year increase of 563.15% [8] - New Light Optoelectronics expects a net loss of 19 million to 23 million yuan for the first half of 2025 [9] - Aihua Pharmaceutical's two probiotic powder registration applications have been accepted [10] Group 4 - Xinhui Electric's subsidiary signed a product sales framework contract for commercial and household robots [11] - Baida Precision Engineering's subsidiary obtained 134,500 square meters of industrial land use rights [12] - Haiyang Technology's chief engineer resigned for personal reasons [13] Group 5 - Tianhe Magnetic Materials received a project filing notice for a 12,000-ton magnetic material deep processing project [22] - Wanlima is the pre-selected unit for a procurement project worth 43.835 million yuan from China Southern Airlines [24] - Yipin Hong's subsidiaries obtained two drug registration certificates [25] Group 6 - Zhejiang Jiaoke's subsidiary signed new construction projects worth 4.783 billion yuan in the second quarter [27] - Shenglan Co. received approval for issuing convertible bonds [29] - Jimi Technology expects a net profit of 88.6622 million yuan for the first half of 2025, a year-on-year increase of 2062.33% [31] Group 7 - Dingtong Technology reported a net profit of 115 million yuan for the first half of 2025, a year-on-year increase of 134.06% [32] - Huaheng Biological is planning to list on the Hong Kong Stock Exchange [34] - Yuntian Lihui submitted an application for H-share issuance and listing on the Hong Kong Stock Exchange [36] Group 8 - Nanchip Technology expects a net profit of 108.8 million to 133.1 million yuan for the first half of 2025, a decrease of 35.09% to 47.03% year-on-year [43] - Anglikang's Mesobam injection has received a drug registration certificate [44] - Jida Zhengyuan's shareholder plans to reduce their stake by up to 0.998% [45]

2024年1至12月份，福元医药的营业收入构成为：药品制剂占比93.12%，医疗器械占比6.46%，其他业 务占比0.36%，其他占比0.06%。 福元医药（SH 601089，收盘价：24.13元）7月31日晚间发布公告称，近日，北京福元医药股份有限公 司收到了国家药品监督管理局颁发的兰索拉唑肠溶胶囊《药品注册证书》，批准该药品生产。 （文章来源：每日经济新闻） ...

Core Viewpoint - Fuyuan Pharmaceutical (601089.SH) has received the drug registration certificate from the National Medical Products Administration for Lansoprazole enteric-coated capsules, indicating approval for production [1] Company Summary - The approved Lansoprazole enteric-coated capsules are available in two specifications: 15mg and 30mg [1] - Lansoprazole was developed by Takeda and was first approved for sale in France on December 31, 1990 [1] - The drug was approved for domestic sale in China on December 6, 1996, and is indicated for conditions such as gastric ulcers, duodenal ulcers, gastroesophageal reflux disease, Zollinger-Ellison syndrome, and anastomotic ulcers [1] Industry Summary - The approval of Lansoprazole enteric-coated capsules reflects ongoing regulatory support for pharmaceutical products aimed at treating gastrointestinal disorders [1]

证券代码：601089 证券简称：福元医药 公告编号：临 2025-054 北京福元医药股份有限公司 关于兰索拉唑肠溶胶囊获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 公司于 2024 年 4 月 25 日获得申报受理通知书，并于近日获得国 家药监局批准。根据国家相关政策规定，本次获得《药品注册证书》， 为视同通过一致性评价。 截至本公告日，公司针对该药品累计研发投入为人民币 583.23 万元(未经审计)。 三、同类药品的市场状况 米内网数据显示，2024 年中国三大终端六大市场兰索拉唑（口服 剂型：胶囊剂、片剂）的销售额约为 100,571 万元，其中城市公立医 院和县级公立医院销售额为 73,807 万元，城市社区中心和乡镇卫生院 销售额为 16,080 万元，城市实体药店和网上药店销售额为 10,684 万 元。 四、对公司的影响及风险提示 近日，北京福元医药股份有限公司（以下简称"公司"）收到了 国家药品监督管理局（以下简称"国家药监局"）颁发的兰索拉唑肠 溶胶囊（规格：15mg；30mg ...

Core Viewpoint - The company has received the drug registration certificate for Lansoprazole enteric-coated capsules, which will enhance its product line and market competitiveness [1] Group 1 - The National Medical Products Administration has issued a drug registration certificate for Lansoprazole enteric-coated capsules in 15mg and 30mg specifications [1] - The drug is considered to have passed the consistency evaluation, indicating its quality and efficacy [1] - The total R&D investment for this drug by the company amounts to RMB 5.8323 million [1]

A股辅助生殖板块持续走强，福元医药盘中创历史新高，共同药业、汉商集团、利德曼涨停，安科生物 涨超15%，广生堂涨超10%，新光药业、达嘉维康、贝因美、星昊医药、贝瑞基因跟涨。 ...

今日焦点 宁德时代：上半年实现净利润305亿元同比增长33.02% 宁德时代公告，上半年实现收入1789亿元，同比增加7.27%；净利润305亿元，同比增长33.02%。报告 期内，本集团实现毛利448亿元，相比2024年同期增加14.45%；综合毛利率为25.02%，相比2024年同期 的23.45%上升1.57个百分点。 上纬新材：多次触及股票交易异常波动和严重异常波动情形明起停牌核查 上纬新材公告称，公司股票自2025年7月9日至7月30日期间多次触及股票交易异常波动及严重异常波动 情形。公司将于7月31日开市起停牌，预计停牌时间不超过3个交易日。公司基本面未发生重大变化，但 股票交易价格已严重脱离基本面，投资者参与交易可能面临较大市场风险。此外，公司股票价格涨幅显 著高于同期相关指数涨幅，换手率显著高于前期水平，市盈率显著高于行业平均水平。公司主营业务和 生产经营未发生重大变化，收购方未来十二个月内不存在资产重组计划，但控制权变更事项仍存在重大 不确定性风险。 金橙子：筹划购买萨米特光电55%股权，股票停牌 金橙子公告称，公司正在筹划以发行股份及支付现金的方式购买长春萨米特光电科技有限公司55%的股 ...

证券日报网讯 7月30日晚间，福元医药发布公告称，公司下属全资子公司福元药业有限公司获得国家药 品监督管理局核准签发的"水杨酸苯酚贴膏"（简称"该药品"）《药品补充申请批准通知书》，该药品上 市许可持有人由西安康华药业有限公司变更为福元药业有限公司。 （编辑 任世碧） ...

证券代码：601089 证券简称：福元医药 公告编号：临 2025-053 北京福元医药股份有限公司 关于子公司获得药品补充申请批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 北京福元医药股份有限公司(以下简称"公司") 下属全资子公司 福元药业有限公司获得国家药品监督管理局（以下简称"国家药监局"） 核准签发的"水杨酸苯酚贴膏"（以下简称"该药品")《药品补充申 请批准通知书》，该药品上市许可持有人由西安康华药业有限公司变 更为福元药业有限公司。现将相关情况公告如下： 一、通知书基本信息 受理号：CYHB2501310 通知书编号：2025B03449 上市许可持有人：福元药业有限公司 生产企业：福元药业有限公司 审批结论：根据《中华人民共和国药品管理法》及有关规定，经 审查，本品此次申请事项符合药品注册的有关要求，同意按照《药品 上市后变更管理办法（试行）》相关规定，批准本品上市许可持有人 由"西安康华药业有限公司"变更为"福元药业有限公司"，药品批 准文号不变。转让药品的生产场地、处方、生产工艺、质量 ...